John Young - Pfizer Group President of Global Established Pharma Bus.
| PFE Stock | MXN 552.00 3.00 0.55% |
President
Mr. John D. Young is the Group President Pfizer Innovative Health and Angela Hwang of Pfizer Inc, effective January 1, 2018. He was Group President, Global Established Pharma Business from January 2014 until June 2016. President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Units Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until 2009. Director of Johnson Controls International plc. since 2018.
| Age | 58 |
| Tenure | 7 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
John Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Young against Pfizer stock is an integral part of due diligence when investing in Pfizer. John Young insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Young over six months ago Ambarella exotic insider transaction detected | ||
John Young over a year ago Acquisition by John Young of 1017 shares of Exelon subject to Rule 16b-3 | ||
John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 | ||
John Young over a year ago Acquisition by John Young of 1029 shares of Exelon subject to Rule 16b-3 |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1332 % which means that it generated a profit of $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3687 %, meaning that it generated $0.3687 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Hans Vestberg | Verizon Communications | 58 | |
| Brett Hart | United Airlines Holdings | 53 | |
| Andrew Iaboni | McEwen Mining | 41 | |
| Brady Connor | Verizon Communications | N/A | |
| Gerald Laderman | United Airlines Holdings | 65 | |
| Robert Jordan | Southwest Airlines | 62 | |
| Michael Ven | Southwest Airlines | 61 | |
| Matthew Ellis | Verizon Communications | 52 | |
| Andrew Nocella | United Airlines Holdings | 53 | |
| Linda Jojo | United Airlines Holdings | 58 | |
| Andrew Watterson | Southwest Airlines | 56 | |
| Tammy Romo | Southwest Airlines | 61 | |
Management Performance
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President of Global Established Pharma Bus. | ||
| Jennifer Damico, Controller VP | ||
| Christopher CFA, VP Officer | ||
| DVM DVM, Chairman CEO | ||
| Frank DAmelio, CFO and Executive VP of Bus. Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Mikael MD, Dev Research | ||
| David Denton, Chief VP |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 5.97 T | |||
| Shares Outstanding | 5.61 B | |||
| Shares Owned By Institutions | 70.47 % | |||
| Price To Earning | 27.15 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 59.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Pfizer Stock Analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.